Uploaded August 2026 | Updated September 2026, 2 weeks ago
"Psychedelics, Cannabis & Trauma-Informed Veterans Care: The Future of PTSD & TBI Treatment" panel discussion at CannMed 2026, covering veteran mental health, PTSD treatment, and psychedelic-assisted therapy.
Sponsored by Veterans Initiative 22
As rates of PTSD, depression, anxiety, sleep disorders, and traumatic brain injury (TBI) continue to rise among veterans and trauma-impacted populations, a new generation of psychedelic-assisted therapies is reshaping the future of mental health care.
This panel explores how MDMA, psilocybin, and ketamine therapies, when paired with cannabis and holistic integration practices, are creating new treatment pathways grounded in clinical evidence, neuroplasticity research, and real-world patient outcomes.
Featuring leaders in psychedelic research, veteran advocacy, and public policy, the discussion examines what's working today, what barriers remain, and how responsible, scalable access can be built across clinical settings, state programs, and federal frameworks.
Attendees will gain insight into best practices for trauma-informed care, ethical and regulatory considerations, and how to responsibly integrate psychedelic and cannabis therapies into veteran-focused mental health treatment models.
Panelists:
Shanetha Lewis (Moderator), Executive Director, Veterans Initiative 22, Chair of Government Relations, MD Task Force on the Responsible Use of Natural Psychedelic Substances
Gary Hess, Founder/Executive Director, Veterans Alliance for Holistic Alternatives
Sue Sisley, MD, Principal Investigator/Chief Medical Officer, Scottsdale Research Institute/Field To Healed Foundation
Laura Barrett, MBA, BSN, RN, Ask Nurse Laura, D4DPR Plant Medicine Nurse Executive
Jason Moore-Brown, Vice President-Strategic Initiatives, Weedmaps
This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.
"Psychedelics, Cannabis & Trauma-Informed Veterans Care: The Future of PTSD & TBI Treatment" panel discussion at CannMed 2026, covering veteran mental health, PTSD treatment, and psychedelic-assisted therapy.
Sponsored by Veterans Initiative 22
As rates of PTSD, depression, anxiety, sleep disorders, and traumatic brain injury (TBI) continue to rise among veterans and trauma-impacted populations, a new generation of psychedelic-assisted therapies is reshaping the future of mental health care.
This panel explores how MDMA, psilocybin, and ketamine therapies, when paired with cannabis and holistic integration practices, are creating new treatment pathways grounded in clinical evidence, neuroplasticity research, and real-world patient outcomes.
Featuring leaders in psychedelic research, veteran advocacy, and public policy, the discussion examines what's working today, what barriers remain, and how responsible, scalable access can be built across clinical settings, state programs, and federal frameworks.
Attendees will gain insight into best practices for trauma-informed care, ethical and regulatory considerations, and how to responsibly integrate psychedelic and cannabis therapies into veteran-focused mental health treatment models.
Panelists:
Shanetha Lewis (Moderator), Executive Director, Veterans Initiative 22, Chair of Government Relations, MD Task Force on the Responsible Use of Natural Psychedelic Substances
Gary Hess, Founder/Executive Director, Veterans Alliance for Holistic Alternatives
Sue Sisley, MD, Principal Investigator/Chief Medical Officer, Scottsdale Research Institute/Field To Healed Foundation
Laura Barrett, MBA, BSN, RN, Ask Nurse Laura, D4DPR Plant Medicine Nurse Executive
Jason Moore-Brown, Vice President-Strategic Initiatives, Weedmaps
This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.
